Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results.
Affiliation
University Hospital Rotterdam, Department of Pulmonary Diseases. P.O. Box 5201, 3008 AE Rotterdam, The Netherlands.Issue Date
2002-08-27
Metadata
Show full item recordAbstract
Patients who are treated within clinical trials may have a survival benefit dependent on being a trial participant. A number of factors may produce such beneficial outcome including more rigorous adherence to a peer reviewed trial protocol, management by an experienced treatment team, being treated in a specialist centre etc. The current investigation compared patients treated on and off trial with the same standard arm treatment regimen. The results could then be interpreted without the confounding factors of differing treatment regimens, treatment teams or treatment hospitals. The results demonstrated given these circumstances that survival was no different for patients participating in a randomised trial compared with a group of patients similarly treated who were not eligible for trial entry or who declined randomisation. These results were obtained by the rigorous adherence to a defined protocol with the invaluable assistance of designated lung cancer staff.Citation
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results. 2002, 87 (5):562-6 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6600433PubMed ID
12189557Type
ArticleLanguage
enISSN
0007-0920ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6600433
Scopus Count
Collections
Related articles
- Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
- Authors: Joss RA, Bacchi M, Hürny C, Bernhard J, Cerny T, Martinelli G, Leyvraz S, Senn HJ, Stahel R, Siegenthaler P
- Issue date: 1995 Feb
- Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
- Authors: Joss RA, Alberto P, Hürny C, Bacchi M, Leyvraz S, Thürlimann B, Cerny T, Martinelli G, Stahel R, Ludwig C
- Issue date: 1995 Jan
- Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
- Authors: Osterlind K, Hansen M, Hirsch FR, Dombernowsky P, Sörenson S, Pedersen AG, Hansen HH
- Issue date: 1991 Jan
- Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
- Authors: Bunn PA Jr, Greco FA, Einhorn L
- Issue date: 1986 Sep
- Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
- Authors: Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D
- Issue date: 1999 Aug